Onconova Therapeutics (ONTX) Rating Lowered to Hold at Maxim Group

Onconova Therapeutics (NASDAQ:ONTX) was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating in a report issued on Wednesday, Marketbeat.com reports.

Several other equities analysts have also weighed in on ONTX. HC Wainwright set a $6.00 target price on shares of Onconova Therapeutics and gave the company a “buy” rating in a report on Thursday, January 4th. Zacks Investment Research upgraded shares of Onconova Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $7.33.

Shares of Onconova Therapeutics (NASDAQ ONTX) opened at $1.89 on Wednesday. Onconova Therapeutics has a one year low of $1.21 and a one year high of $3.88. The stock has a market cap of $20.36, a PE ratio of -0.62 and a beta of 0.10.

Onconova Therapeutics (NASDAQ:ONTX) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.02. Onconova Therapeutics had a negative net margin of 2,855.94% and a negative return on equity of 558.97%. The company had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.29 million. analysts predict that Onconova Therapeutics will post -2.82 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the business. Tyndall Capital Partners L P boosted its holdings in Onconova Therapeutics by 91.4% in the 2nd quarter. Tyndall Capital Partners L P now owns 997,022 shares of the biopharmaceutical company’s stock valued at $2,154,000 after purchasing an additional 476,190 shares during the last quarter. Sabby Management LLC boosted its holdings in Onconova Therapeutics by 104.0% in the 2nd quarter. Sabby Management LLC now owns 784,000 shares of the biopharmaceutical company’s stock valued at $1,693,000 after purchasing an additional 399,640 shares during the last quarter. 683 Capital Management LLC boosted its holdings in Onconova Therapeutics by 21.0% in the 3rd quarter. 683 Capital Management LLC now owns 375,000 shares of the biopharmaceutical company’s stock valued at $641,000 after purchasing an additional 65,140 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Onconova Therapeutics by 58.4% in the 2nd quarter. Vanguard Group Inc. now owns 87,940 shares of the biopharmaceutical company’s stock valued at $190,000 after purchasing an additional 32,418 shares during the last quarter. Institutional investors own 25.44% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Onconova Therapeutics (ONTX) Rating Lowered to Hold at Maxim Group” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.com-unik.info/2018/01/19/onconova-therapeutics-ontx-rating-lowered-to-hold-at-maxim-group.html.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit